Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives

Ema Ozaki,1 Matthew Campbell,1 Sarah L Doyle2,3 1Department of Genetics, 2Department of Clinical Medicine, School of Medicine, Trinity College Dublin, 3National Children's Research Centre, Our Lady's Children's Hospital Crumlin, Dublin, Ireland Abstract: The inflammasome is...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ozaki E, Campbell M, Doyle SL
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/db090e7b71ab4be5a2c720688d371a9f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:db090e7b71ab4be5a2c720688d371a9f
record_format	dspace
spelling	oai:doaj.org-article:db090e7b71ab4be5a2c720688d371a9f2021-12-02T06:14:45ZTargeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives1178-7031https://doaj.org/article/db090e7b71ab4be5a2c720688d371a9f2015-01-01T00:00:00Zhttp://www.dovepress.com/targeting-the-nlrp3-inflammasome-in-chronic-inflammatory-diseases-curr-peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031 Ema Ozaki,1 Matthew Campbell,1 Sarah L Doyle2,3 1Department of Genetics, 2Department of Clinical Medicine, School of Medicine, Trinity College Dublin, 3National Children's Research Centre, Our Lady's Children's Hospital Crumlin, Dublin, Ireland Abstract: The inflammasome is a molecular platform formed by activation of an innate immune pattern recognition receptor seed, such as NLRP3. Once activated, NLRP3 recruits the adapter ASC (apoptosis-related speck-like protein containing a caspase recruitment domain), which in turn recruits procaspase-1. Procaspase-1 autocatalyzes its cleavage and activation, resulting in maturation of the precursor forms of interleukin (IL)-1β and IL-18 into active proinflammatory cytokines and initiation of pyroptotic cell death. The NLRP3 inflammasome has been implicated in the pathogenesis of a wide variety of diseases, including genetically inherited autoinflammatory conditions as well as chronic diseases in which NLRP3 is abnormally activated. The NLRP3 inflammasome has been linked to diseases such as Alzheimer's disease, atherosclerosis, metabolic syndrome, and age-related macular degeneration. In this review, we describe the NLRP3 inflammasome complex and its activation in disease, and detail the current therapies that modulate either the NLRP3 inflammasome complex itself or the two cytokines it is responsible for activating, ie, IL-1β and IL-18. Keywords: NLRP3, interleukin-1, interleukin-18, caspase-1, therapeutics, inflammasomeOzaki ECampbell MDoyle SLDove Medical PressarticlePathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol 2015, Iss default, Pp 15-27 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Ozaki E Campbell M Doyle SL Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives
description	Ema Ozaki,1 Matthew Campbell,1 Sarah L Doyle2,3 1Department of Genetics, 2Department of Clinical Medicine, School of Medicine, Trinity College Dublin, 3National Children's Research Centre, Our Lady's Children's Hospital Crumlin, Dublin, Ireland Abstract: The inflammasome is a molecular platform formed by activation of an innate immune pattern recognition receptor seed, such as NLRP3. Once activated, NLRP3 recruits the adapter ASC (apoptosis-related speck-like protein containing a caspase recruitment domain), which in turn recruits procaspase-1. Procaspase-1 autocatalyzes its cleavage and activation, resulting in maturation of the precursor forms of interleukin (IL)-1β and IL-18 into active proinflammatory cytokines and initiation of pyroptotic cell death. The NLRP3 inflammasome has been implicated in the pathogenesis of a wide variety of diseases, including genetically inherited autoinflammatory conditions as well as chronic diseases in which NLRP3 is abnormally activated. The NLRP3 inflammasome has been linked to diseases such as Alzheimer's disease, atherosclerosis, metabolic syndrome, and age-related macular degeneration. In this review, we describe the NLRP3 inflammasome complex and its activation in disease, and detail the current therapies that modulate either the NLRP3 inflammasome complex itself or the two cytokines it is responsible for activating, ie, IL-1β and IL-18. Keywords: NLRP3, interleukin-1, interleukin-18, caspase-1, therapeutics, inflammasome
format	article
author	Ozaki E Campbell M Doyle SL
author_facet	Ozaki E Campbell M Doyle SL
author_sort	Ozaki E
title	Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives
title_short	Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives
title_full	Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives
title_fullStr	Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives
title_full_unstemmed	Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives
title_sort	targeting the nlrp3 inflammasome in chronic inflammatory diseases: current perspectives
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/db090e7b71ab4be5a2c720688d371a9f
work_keys_str_mv	AT ozakie targetingthenlrp3inflammasomeinchronicinflammatorydiseasescurrentperspectives AT campbellm targetingthenlrp3inflammasomeinchronicinflammatorydiseasescurrentperspectives AT doylesl targetingthenlrp3inflammasomeinchronicinflammatorydiseasescurrentperspectives
_version_	1718400022058369024

Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives

Ejemplares similares